Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
In this month’s “Virtual Lecture,” Sean Pittock, M.D., discusses the rapidly evolving field of autoimmune neurology helping physicians quickly and accurately diagnose this treatable patient population.
In this month’s “Hot Topic,” Sean Pittock, M.D., explains Neuromyelitis Optica Spectrum Disorder (NMOSD) and the critical importance of a sensitive and specific AQP4-IgG laboratory test for early diagnosis and treatment.
Mayo Clinic Laboratories has launched a first-in-the-U.S. autoimmune test of the Kelchlike protein 11 antibody, or KLHL11, which is used to detect autoimmune disease associated with testicular cancer.
In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.
Andrew McKeon, M.B., B.Ch., M.D., discusses updates that are being made to Mayo Clinic Laboratories' autoimmune profile that will remove some antibodies from those profiles. He describes the rationale behind the updates, reviews which antibodies are involved, and explains how the changes will streamline testing and enhance test interpretation.
Based on studies that have shown certain antibodies may not be as clinically relevant to autoimmune testing as previously thought, Mayo Clinic Laboratories is updating a number of its autoimmune profiles by removing some antibodies from them.
Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in patients with atypical presentation.
In this month’s “Hot Topic,” John Mills, Ph.D., explains the central role of tissue immunofluorescence in the identification of neural antibodies and discusses the benefits of an integrated laboratory approach to the development and validation of novel antibody biomarkers.
Andrew McKeon, M.B., B.Ch., M.D, gives an overview of the new glycine receptor antibody test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
In this month’s “Virtual Lecture,” Andrew McKeon, M.B., B.Ch., M.D., highlights the rapidly evolving field of autoimmune neurology. The importance of a timely and accurate diagnosis of autoimmune neurological disorders cannot be understated, so it is important that neurologists all understand the patient presentation as well as available testing and treatment options.